ПРАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ИСПОЛЬЗОВАНИЮ СУНИТИНИБА В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО РАКА ПОЧКИ. НЕЖЕЛАТЕЛЬНЫЕ ЯВЛЕНИЯ – ПОТЕНЦИАЛЬНЫЕ МАРКЕРЫ ЭФФЕКТИВНОСТИ
Аннотация
Статья посвящена особенностям переносимости сунитиниба при лечении метастатического почечно-клеточного рака. Подробно рассмотрены побочные эффекты препарата, являющиеся потенциальными биомаркерами его эффективности.
Ключевые слова
Об авторах
Г. Ю. Харкевич
ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
Л. В. Демидов
ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
Список литературы
1. Schmidinger M., Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Canc Treat Rev 2010;36:416–24.
2. Escudier B., Eisen T., Porta C. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of oncology 2012;23 (Suppl 7):vii 65–71.
3. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 2.2012.
4. Практические рекомендации по лекарственному лечению злокачественных опухолей (RUSSCO). Под ред. В.М. Моисеенко. М.: Общество онкологов химиотерапевтов, 2012; с.164–166.
5. Gore M.E., Szczylik C., Porta C. et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757–63.
6. Houk B.E., Bello C.L., Poland B. et al. Relationshi p between exposure to sunitinib and efficacy and tolerability andpoints in patients with cancer: results of a pharmacokinetic/ pharmacodynamic meta-analysis. Canc Chemother Pharmacol 2010;66:357–71.
7. Motzer R.J., Hutson T.E., Olsen M.R. et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30(12):1371–7.
8. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356:115–24.
9. Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–90.
10. Porta C., Szczylik C., Bracarda S. et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. J Clin Oncol 2008;26: abstr 5114.
11. Motzer R.J., Michaelson M.D., Redman B.G. et al. Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16–24.
12. Motzer R.J., Rini B.I., Bukowski R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295;21:2516–24.
13. Castellano D., Ravaud A., Schmidinger M. et al. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concept and the impact of clinical biomarkers. Cancer Treatment Reviews 2012; in press.
14. Sica D.A. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006;24:1329–31.
15. Bhargava P. VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 2009;297:1–5.
16. Rini B.I., Cohen D.P., Lu D.R. et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib, J Natl Cancer Inst 2011;103:763–73.
17. Appleby L., Morrissey S., Bellmunt J., Rosenberg J. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practices. Hemato l Oncol Clin Am 2011;25:893–915.
18. Kollmannsberger C., Bjarnason G., Burnett P. et al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. The Oncologist 2011;16:543–53.
19. Michaelson M.D., Cohen D.P., Li S. et al. Hand-foot syndrome as a potential biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Clin Oncol 2011;29(Suppl 7):abstr 320.
20. Wolter P., Stefan C., Decallonne B. et al. The clinical implication of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cance r 2008;99:448–54.
21. Rini B.I., Tamaskar I., Shaheen P. et al. Hupothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81–3.
22. Schmidinger M., Vogl U., Bojic M. et al. Hypothyroidism in patients renal cell carcinoma. Cancer 2011;117:534–44.
23. Hercbergs A., Goyal L.K., Suh J.H. et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res 2003;23:617–6.
24. Nelson M., Hercbergs A., Rybicki L. et al. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132:1041–6.
25. Hercbergs A., Werner A., Brenner H.J. Does hypothyroidism favor the response to therapy in metastatic breast cancer? Proc ASCO 1988;7:A77.
26. Wolter P., Stephan C., Decallonne B. et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients with advanced renal cell cancer. J Clin Oncol 2008;26S; abstr 5126.
27. Donskov F., Michaelson M.D., Puzano v I. et al. Comparative assessment of sunitinib-associated adverse events as potential biomarkers of efficacy in metastatic renal cell carcinoma. Annals of oncology 2012;23 (Suppl 9): ix259; abstr 7850.
Для цитирования:
Харкевич Г.Ю., Демидов Л.В. ПРАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ИСПОЛЬЗОВАНИЮ СУНИТИНИБА В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО РАКА ПОЧКИ. НЕЖЕЛАТЕЛЬНЫЕ ЯВЛЕНИЯ – ПОТЕНЦИАЛЬНЫЕ МАРКЕРЫ ЭФФЕКТИВНОСТИ. Онкоурология. 2013;9(2):26-34. https://doi.org/10.17650/1726-9776-2013-9-2-26-34
For citation:
Kharkevich G.Y., Demidov L.V. PRACTICAL RECOMMENDATIONS FOR THE USE OF SUNITINIB IN THE TREATMENT OF METASTATIC KIDNEY CANCER. ADVERSE EVENTS – POTENTIAL MARKERS OF ITS EFFICACY. Cancer Urology. 2013;9(2):26-34. (In Russ.) https://doi.org/10.17650/1726-9776-2013-9-2-26-34
Просмотров: 406
Послать статью по эл. почте 
